CKD announced on May 21 that it held the "2026 CKD Pharm Golden Ticket" event at the LabCentral Center in Boston on May 20, awarding the "Golden Ticket" to the biotech company Arpelos Biosciences.
The "CKD Pharm Golden Ticket" is a sponsorship program hosted by CKD and operated in collaboration with LabCentral, a key institution in the Boston-Cambridge biotech cluster. The program provides promising biotech startups with opportunities to join LabCentral and access a global network, evolving into a global open innovation platform that proactively identifies early-stage innovative technologies. Open innovation is recognized as a strategy that reduces the risks of drug development and secures promising biotech technologies in advance.
The event was attended by CKD Vice President Kim Jae-soon, CKD USA Corporate Director Kim Ho-won, Consul General of Boston Kim Jae-hwi, and Kim Hyun-cheol, Director of the Korea Health Industry Development Institute's U.S. branch.
Arpelos Biosciences, selected for this year's award, is an early-stage biotech company founded in 2024. It is focused on developing next-generation treatments for autoimmune diseases based on artificial intelligence (AI)-driven protein engineering, T-cell biology, and multi-therapeutic development technologies.
This year, approximately 50 biotech startups from various fields, including immunology, neuroscience, tumor and cancer immunotherapy, ophthalmic diseases, and AI-based research platforms, applied for the program, with three finalists competing for the award.
LabCentral is a nonprofit organization managed by the Massachusetts state government and serves as a global incubator for biotech startups. It has supported over 344 early-stage companies to date, resulting in 1,846 patents and 171 clinical trial outcomes as of 2025.
A CKD representative stated, "The Golden Ticket is an important gateway for proactively discovering promising biotech companies, and we aim to create tangible collaborative results through the expansion of our global network and joint research and development."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.